整合酶链转移抑制剂在非洲围产期HIV-1感染儿童中的预测疗效
研究纳入中非共和国18名接受一线或二线cART后病毒学失败的INSTI初治HIV感染儿童和青少年,通过基因型分析评估INSTI耐药突变。结果显示88.9%的病毒对主要INSTI完全敏感,仅2例(11.1%)携带主要INSTI耐药突变,提示INSTI可作为非洲儿童一线或后续治疗方案的选择。
要点
- 88.9%的HIV-1整合酶序列对主要INSTI完全敏感
- 仅2例(11.1%)携带主要INSTI耐药突变(E138K/E138T)
- 80%的病毒对至少一种WHO推荐的一线或二线药物耐药
核心结论
- INSTI可为大多数非洲儿童或青少年用作一线方案,并可能作为撒哈拉以南非洲HIV感染儿童和青少年的二线和三线cART替代方案。
研究设计与样本
- 在中非共和国班吉Complexe Pédiatrique收集血浆,纳入INSTI初治的HIV感染儿童(n=8)和青少年(n=10),均为一线和/或二线cART治疗5年后病毒学失败(病毒载量>1000 copies/mL)。
- 对整合酶(IN)、逆转录酶(RT)和蛋白酶(P)基因进行基因型分析,使用Stanford算法解读INSTI、NRTI、NNRTI和PI耐药突变。
主要发现
- 成功获得IN、RT和P基因型的儿童分别为18、13和15例(中位年龄11岁,范围5-18;8例女性)。
- 2例(2/18;11.1%)接受一线方案治疗的儿童病毒在 codon 138 存在INSTI耐药突变(E138K和E138T),并伴有辅助突变L74I、G140K、G140R和G163R。
- 大多数(16/18;88.9%)HIV-1 IN序列对全部主要INSTI显示完全敏感,且自然多态性突变频率高。
- 多数(12/15;80%)获得基因型的病毒携带至少一个主要耐药突变,对至少一种WHO推荐的一线或二线方案中使用的抗逆转录病毒药物(NNRTI、NRTI和PI)耐药。
临床怎么用
- 在非洲围产期HIV感染儿童和青少年中,INSTI可作为一线方案的优先选择。
- 对于一线或二线cART失败的儿童,INSTI可作为二线或三线cART的相关治疗替代方案。
局限性
- 样本量小(INSTI基因型仅18例),可能影响结果的代表性。
- 仅来自中非共和国班吉单一中心,外推至其他非洲地区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The predictive efficacy of integrase (IN) strand transfer inhibitors (INSTIs) was investigated in HIV-infected children born to HIV-infected mothers in Africa. METHODS: Plasma was collected at the Complexe Pédiatrique of Bangui, Central African Republic, from INSTI-naive children (n = 8) and adolescents (n = 10) in virological failure (viral load >1000 copies/mL) after 5 years of first- and/or second-line combination ART (cART). IN, reverse transcriptase (RT) and protease (P) genes were genotyped and drug resistance mutations (DRMs) to INSTIs, NRTIs, NNRTIs and PIs were interpreted using the Stanford algorithm. RESULTS: Successful IN, RT and P genotypes were obtained for 18, 13 and 15 children (median age 11 years, range 5-18; 8 were female), respectively. Two (2/18; 11.1%) viruses from children treated with a first-line regimen had INSTI DRMs at codon 138 (E138K and E138T), which is known to harbour major resistance mutations, and also had the accessory mutations L74I, G140K, G140R and G163R. The majority (16/18; 88.9%) of HIV-1 IN sequences demonstrated full susceptibility to all major INSTIs with a high frequency of natural polymorphic mutations. Most (12/15; 80%) genotyped viruses harboured at least one major DRM conferring resistance to at least one of the WHO-recommended antiretroviral drugs (NNRTIs, NRTIs and PIs) prescribed in first- and second-line regimens. CONCLUSIONS: INSTIs could be proposed in first-line regimens in the majority of African children or adolescents and may constitute relevant therapeutic alternatives as second- and third-line cART regimens in HIV-infected children and adolescents living in sub-Saharan Africa.
引用
- Mboumba Bouassa RS, Mossoro-Kpinde CD, Gody JC, et al. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO. J Antimicrob Chemother. 2019. PMID: 30891603. doi:10.1093/jac/dkz099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。